Group One Trading’s Cytek Biosciences CTKB Stock Holding History

Group One Trading’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.11K	Sell	250 -1,950	-89%	-$8.32K	﹤0.01%	7163
2026 Q1	$9.61K	Buy	2,200 +700	+47%	+$3.31K	﹤0.01%	6396
2025 Q4	$7.58K	Buy	+1,500	New	+$6.96K	﹤0.01%	6969
2024 Q2	–	Sell	-8,377	Closed	-$56.2K	–	6842
2024 Q1	$56.2K	Buy	8,377 +884	+12%	+$6.99K	﹤0.01%	4620
2023 Q4	$68.3K	Buy	+7,493	New	+$47.2K	﹤0.01%	4807
2023 Q1	–	Sell	-61	Closed	-$623	–	7318
2022 Q4	$623	Buy	+61	New	+$820	﹤0.01%	6918

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Group One Trading's CTKB Position: Q2 2026 in Review

Group One Trading reduced its Cytek Biosciences (CTKB) stake by 89% in Q2 2026, selling an estimated $8.32K and leaving 250 shares worth $1.11K. The position accounts for ﹤0.01% of the portfolio, ranked #7163.

Group One Trading first reported a position in CTKB in Q4 2022 and has held it in 6 quarters since. The position peaked at $68.3K in Q4 2023. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Group One Trading held 250 shares of Cytek Biosciences worth $1.11K as of Q2 2026.
Group One Trading sold 1,950 Cytek Biosciences shares in Q2 2026, an estimated $8.32K.
Cytek Biosciences made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7163 holding.
Group One Trading first reported a position in Cytek Biosciences in Q4 2022 and has held it in 6 quarters since.
Group One Trading's Cytek Biosciences position peaked at $68.3K in Q4 2023.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.